<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033096</url>
  </required_header>
  <id_info>
    <org_study_id>64,185-203</org_study_id>
    <nct_id>NCT02033096</nct_id>
  </id_info>
  <brief_title>Follow-up, Blinded-Outcomes Trial of Subjects Having Received IMP in Clinical Trial 64,185-202</brief_title>
  <official_title>A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202 Trial Number: 64,185-203 Trial Phase:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InfaCare Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InfaCare Pharmaceuticals Corporation</source>
  <brief_summary>
    <textblock>
      Follow-up, Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>long term effects of stannsoporfin treatment on adverse events</measure>
    <time_frame>48 to 54 months</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Jaundice</condition>
  <condition>Neonatal Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stannsoporfin 1.5 mg/kg</arm_group_label>
    <description>received 1.5 mg/kg in study 202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stannsoporfin3.0 mg/kg</arm_group_label>
    <description>received 1.5 mg/kg in study 202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stannsoporfin 4.5 mg/kg</arm_group_label>
    <description>stannsoporfin 4.5 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stannsoporfin</intervention_name>
    <arm_group_label>stannsoporfin 1.5 mg/kg</arm_group_label>
    <arm_group_label>stannsoporfin3.0 mg/kg</arm_group_label>
    <arm_group_label>stannsoporfin 4.5 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have received stansaporfin in clinical trial 64,185-202
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have received IMP in clinical trial 64,185-202 â€¢ Written informed
             consent provided by parents/guardians

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Ruiz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>InfaCare Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 6, 2016</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stannsoporfin</keyword>
  <keyword>hyperbilirubinemia</keyword>
  <keyword>heme oxygenase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
